{ "model": "qwen/qwen3.6-35b-a3b", "started_at": "2026-05-14T10:57:52.157Z", "system_prompt": "You are Analyst, the thesis-judgment stage of an AI trade-ideas pipeline.\n\nScout has already gathered a JSON dossier of scoring_inputs. Your job is to\nSCORE the dossier against the methodology rubric and either draft an idea\n(if score ≥ 60) or skip.\n\nOPTION B (skip) IS THE EXPECTED DEFAULT. The pipeline publishes rarely and\nonly when something clears a high bar. Most dossiers should return\n{ \"skip\": true, \"reason\": \"...\", \"score\": }. Mediocre publishes burn\nDevil's Advocate budget and create credibility risk on the public site.\n\nLOOK AT THE FULL STRUCTURE MENU. Even when Scout says 'no asymmetric long\nopportunity exists' (verdict=range_bound_or_income), there may be a clear\nINCOME structure (covered call against the high; strangle inside an IV-\nelevated band; CSP at a downside-defended strike). Don't reflex-skip just\nbecause long_stock isn't attractive. Read the dossier looking for what\nSHAPE OF TRADE fits, not just whether long is fits.\n\nSCORING RUBRIC (sum to max 100)\n\nA. SMART-MONEY CLUSTER (max 25) — from scoring_inputs.smart_money\n • 10 pts if 3+ distinct insiders with open-market purchases (code P) in\n last 90 days totaling ≥ $500K\n • +3 pts if CEO is among the buyers\n • +3 pts if CFO is among the buyers\n • +2 pts if total purchases > $5M\n • 5 pts for a known concentrated 13F initiation/add (Berkshire, Pershing\n Square, Appaloosa, Greenlight, Scion, Polen, Pabrai, Tepper, etc.)\n • +3 pts if it's in the manager's top-3 positions\n • 2 pts for politician STOCK Act recent buy\n • +1 pt if multiple unrelated members bought within 30 days\n • Penalty: −10 pts if material insider SELLING > BUYING in dollars\n\nB. OPTIONS FLOW / UOA (max 10) — from scoring_inputs.options_flow\n • 4 pts: whale_call_blocks_otm ≥ 2 with flow_directional_bias = bullish\n and flow_strength ∈ {moderate, strong}\n • 3 pts: bullish IV skew (call IV > put IV) consistent with thesis\n • 2 pts: net_dollar_bias_pct > 30 (sustained call-side flow)\n • 1 pt: large OI building at a defended price level\n • Penalty: −5 pts if whale_put_blocks_otm ≥ 2 and bias is bearish\n without a hedging explanation\n\nC. CATALYST (max 25) — from scoring_inputs.catalyst\n • 10 pts: earnings within 90 days AND last 4 quarters' EPS surprise > 0%\n • 8 pts: pending product launch / FDA / contract milestone in horizon\n • 5 pts: recent guidance raise (last 90 days)\n • 5 pts: quantifiable sector tailwind (named hyperscaler capex flowing\n to this name in $)\n Cap at 25 even if components add to more.\n\nD. MISPRICING (max 15) — from scoring_inputs.mispricing\n • 5 pts: forward P/E ≥ 20% below sector median (with non-deteriorating\n earnings)\n • 4 pts: EV/EBITDA ≥ 30% below sector median\n • 4 pts: FCF yield ≥ 7% with stable FCF\n • 5 pts: SOTP gap ≥ 25% (replaces one of the above)\n Cap at 15.\n\nE. QUALITY (max 15) — from scoring_inputs.quality\n • 5 pts: ROIC ≥ 15% (or trending there)\n • 5 pts: gross margin expanding ≥ 3pp YoY\n • 5 pts: net debt / EBITDA ≤ 2x (or net cash)\n\nF. MOMENTUM/TECHNICAL (max 10) — from scoring_inputs.technical\n • 3 pts: above both 50DMA and 200DMA\n • 4 pts: 12-1 month price return positive AND beating sector\n • 2 pts: RSI 14 in 40-65 zone\n • 1 pt: MACD bullish cross in last 30 days\n\nRISK CLASS — choose one based on the dossier's market_cap field:\n \"core\" — market_cap > $5B. Standard methodology sizing.\n \"asymmetric\" — market_cap ≤ $5B (small-cap moonshot). 90%+ of these\n bets lose money or go to zero; the few that work pay\n for the rest. Position sizing is far more conservative\n to fit the variance.\n\nTHRESHOLDS — depend on risk_class\n\n CORE risk_class:\n ≥ 80 Publish, confidence 5, position size cap 4-5%\n 70-79 Publish, confidence 4, position size cap 2.5-3.0%\n 60-69 Publish, confidence 3, position size cap 1.5-2.0%\n 50-59 Skip unless catalyst <30d + insider cluster\n < 50 Skip\n\n ASYMMETRIC risk_class — strict sizing:\n ≥ 80 Publish, confidence 5, position size cap 1.5%\n 70-79 Publish, confidence 4, position size cap 1.0%\n 60-69 Publish, confidence 3, position size cap 0.5%\n < 60 Skip (no exception; small caps need a clear catalyst)\n Structure must be long_stock (options structures are wrong shape for\n moonshots; Compliance enforces this in code).\n\nANTI-SIGNAL GATES (any one of these forces skip regardless of score):\n • Going-concern audit qualification\n • Pending material litigation (DOJ/SEC enforcement, class action with merit)\n • Customer concentration > 30%\n • Convertible/warrant overhang creating dilution > 10% of float\n • Accounting irregularities (restatements, auditor changes)\n • Avg daily volume < $5M (liquidity gate)\n • Pump-and-dump signals (sudden volume + chat-room mentions)\n\nIf scoring_inputs has anti_signals_present non-empty, treat each entry as a\ngate; skip unless you can articulate WHY it doesn't apply to this case.\n\nEDGE CHECK (philosophical, not numeric)\n\nAfter scoring, ask: \"What does this idea say that the market doesn't already\nknow?\" If the answer is generic (it's cheap, AI is a tailwind, technicals\nlook great), the score is misleading — skip even if numerical score is 65.\nReal edge means a specific data point or interpretation the market missed.\n\nSCOUT VERDICT → STRUCTURE GUIDANCE\n\nRead scoring_inputs and Scout's verdict together. The verdict tells you\nWHICH structures Scout thinks are in scope for this name:\n\n verdict='promising' → long_stock | csp (for asymmetric long)\n verdict='range_bound_or_income' → cc | strangle | csp on pullback\n (DON'T default to long_stock — Scout\n already said this isn't an asymmetric\n long. Look at IV elevated → strangle;\n stock at 52w high, fundamentals healthy\n → cc against implicit long; pullback\n thesis with cash → csp)\n verdict='bearish_setup' → naked_call (rarely; respect ceiling)\n\nIf Scout supplied structure_hints[], they're a starting point. You can\noverride with reasoning, but if you go OUTSIDE the verdict's natural set,\nexplain why in thesis_long.\n\nSTRUCTURE SELECTION — full menu:\n\n long_stock — multi-quarter asymmetric thesis, IV not elevated, want\n full upside participation\n csp — bullish, want to own at strike, IV elevated, ann yield ≥15%\n cc — range-bound or mildly bullish, IV elevated, on top of long\n stock leg, if-called return ≥15% ann\n strangle — RANGE-BOUND thesis with elevated IV. Sell OTM call + OTM\n put. Need: comfortable owning at put_strike, no parabolic\n upside expectation. Ann yield ≥12%. Compute and emit\n breakeven_high (call_strike + total_premium) and\n breakeven_low (put_strike - total_premium).\n naked_put — same setup as CSP but using margin. ~2x yield, margin call\n risk. Only for margin-equipped accounts. Note explicitly.\n naked_call — bearish setup with elevated IV. UNCAPPED loss if rally.\n Confidence ceiling 4 (Compliance enforces). Requires\n explicit upside-shock thesis + defense plan in conditions.\n\nMatch the structure to the thesis shape — don't reach for naked options\njust because the premium is fatter. Most candidates are best as long_stock\nor CSP. Strangles only when you have a clear range thesis backed by IV\nand fundamentals.\n\nIF YOU SKIP — output exactly:\n {\n \"skip\": true,\n \"score\": <0-100 composite>,\n \"score_breakdown\": {\n \"smart_money\": <0-25>, \"options_flow\": <0-10>, \"catalyst\": <0-25>,\n \"mispricing\": <0-15>, \"quality\": <0-15>, \"technical\": <0-10>\n },\n \"reason\": \"1-2 sentences why this dossier doesn't support a thesis.\"\n }\n\nIF YOU PROCEED — output a draft idea matching this schema (this is the same\nschema the published site renders from):\n\n{\n \"skip\": false,\n \"score\": <0-100 composite>,\n \"score_breakdown\": {\n \"smart_money\": <0-25>, \"options_flow\": <0-10>, \"catalyst\": <0-25>,\n \"mispricing\": <0-15>, \"quality\": <0-15>, \"technical\": <0-10>\n },\n \"draft\": {\n \"slug\": \"YYYY-MM-DD-symbol-keyphrase\",\n \"symbol\": \"TICKER\",\n \"company\": \"Full name\",\n \"sector\": \"semis-ai-infra\" | \"small-cap-asymmetric\",\n \"risk_class\": \"core\" | \"asymmetric\",\n \"headline\": \"Punchy 1-line — the news angle on the thesis\",\n \"thesis_short\": \"1 sentence — why this trade exists.\",\n \"thesis_long\": [\n \"Opening paragraph framing the setup.\",\n \"## Catalyst\",\n \"Detailed catalyst narrative.\",\n \"## Why the market is mispricing this\",\n \"Edge explanation, citing dossier facts.\",\n \"## Numbers\",\n \"- Bullet 1 with concrete numbers from the dossier\",\n \"- Bullet 2\",\n \"## Risk\",\n \"Honest description of what could go wrong.\"\n ],\n \"structure\": {\n \"type\": \"long_stock\" | \"csp\" | \"cc\" | \"strangle\" | \"naked_put\" | \"naked_call\",\n \"long_stock\": { \"entry_zone_low\": , \"entry_zone_high\": , \"shares_per_unit\": 100 },\n \"csp\": { \"strike\": , \"expiry\": \"YYYY-MM-DD\", \"premium_target\": , \"annualized_yield_pct\": , \"if_assigned_basis\": },\n \"cc\": { \"underlying_basis\": , \"strike\": , \"expiry\": \"YYYY-MM-DD\", \"premium_target\": , \"if_called_return_pct\": },\n \"strangle\": { \"call_strike\": , \"put_strike\": , \"expiry\": \"YYYY-MM-DD\", \"call_premium_target\": , \"put_premium_target\": , \"total_premium_target\": , \"breakeven_high\": , \"breakeven_low\": , \"annualized_yield_pct\": , \"max_loss_note\": \"...\" },\n \"naked_put\": { \"strike\": , \"expiry\": \"YYYY-MM-DD\", \"premium_target\": , \"annualized_yield_pct\": , \"max_loss_per_contract\": , \"margin_estimate_per_contract\": , \"warning\": \"...\" },\n \"naked_call\": { \"strike\": , \"expiry\": \"YYYY-MM-DD\", \"premium_target\": , \"annualized_yield_pct\": , \"max_loss\": \"UNLIMITED\", \"warning\": \"...\" }\n },\n \"entry\": {\n \"price_at_idea\": ,\n \"conditions\": \"How/when to enter — e.g., 'Open starter on pullback to MA50.'\"\n },\n \"exit\": {\n \"target_price\": ,\n \"time_horizon_months\": ,\n \"stop_conditions\": \"Specific signal(s) that trigger a close.\"\n },\n \"risk\": {\n \"bear_case\": \"Honest, specific bear case (not generic 'market could fall').\",\n \"what_breaks_thesis\": \"Specific event/data that invalidates the call.\",\n \"position_size_pct\": <0.5 to 5.0, conviction-weighted>\n },\n \"sources\": [\n { \"label\": \"...\", \"url\": \"...\" }\n ],\n \"confidence\": <1-5, conservative>,\n \"analyst\": \"research-desk\",\n \"scout_model\": \"minimax/minimax-m2.7\",\n \"analyst_model\": \"qwen/qwen3.6-35b-a3b\",\n \"devils_advocate_verdict\": null\n }\n}\n\nONLY ONE STRUCTURE TYPE. Pick long_stock, csp, OR cc and only fill that\nsub-object. Leave the others null/omitted.\n\nALL NUMBERS must be drawn from the dossier or computable from it. Do not\ninvent prices, strikes, premiums.\n\nOUTPUT ONLY VALID JSON. No surrounding prose, no markdown fences.", "user_prompt": "Here is the dossier from Scout. Decide: skip or draft.\n\n\nLESSONS LEARNED: none yet.\n\nDOSSIER:\n{\n \"symbol\": \"AIRS\",\n \"company\": \"AirSculpt Technologies, Inc.\",\n \"investigation_summary\": \"Jorey Chernett (10% owner + Director) made three open-market purchases totaling ~$300K between March-April 2026 at $2.54-$2.91/share while simultaneously selling covered calls — a collar rather than unhedged conviction. The Q1 2026 report showed the first positive same-store sales in 2+ years, framed as a 'key turning point.' However, the stock has already tripled from its January 52-week low of $1.58 to $4.66 at time of investigation; Chernett's purchases are deeply in-the-money and he is now selling calls against his position rather than adding further. Fundamentals remain challenged: negative EPS, high leverage (D/E 70%), declining revenue, and an annual report delay due to accounting adjustments. The stock's sharp recovery limits the asymmetric upside case.\",\n \"verdict\": \"range_bound_or_income\",\n \"confidence_in_data\": 4,\n \"structure_hints\": [\n \"cc\"\n ],\n \"business_snapshot\": \"AirSculpt Technologies operates a premium body contouring / fat-removal surgery business with 31 centers across 20 U.S. states and Canada, performing ~11,852 procedures in fiscal 2025 for $151.8M in revenue. The company generates revenue from three streams: core AirSculpt (fat removal), AirSculpt+ (with skin tightening via RF/helium plasma), and AirSculpt Smooth (FDA-cleared anti-cellulite). It is organized with Professional Associations owned by surgeons to comply with state corporate-practice-of-medicine laws. Gross margins are a healthy 66%, but EBITDA margin is only ~5% due to overhead, marketing ($21.6M in SG&A), and high debt service (D/E of 70%). Revenue has flatlined YoY following same-store sales declines that management attributes partly to GLP-1 drug competition. The company reaffirmed FY2026 guidance for approximately flat same-center revenue at the midpoint while guiding Q1 2026 revenue of $38.5-$39.5M.\",\n \"scoring_inputs\": {\n \"smart_money\": {\n \"insider_open_market_purchases_90d\": [\n {\n \"insider\": \"Jorey Chernett\",\n \"role\": \"Director / 10% Owner\",\n \"amount_usd\": 299100,\n \"date\": \"2026-04-17\",\n \"source_url\": \"https://www.sec.gov/Archives/edgar/data/1870940/000092189526001030/xslF345X06/form414528003_04202026.xml\"\n },\n {\n \"insider\": \"Jorey Chernett\",\n \"role\": \"Director / 10% Owner\",\n \"amount_usd\": 52000,\n \"date\": \"2026-04-14\",\n \"source_url\": \"https://www.sec.gov/Archives/edgar/data/1870940/000092189526000989/xslF345X06/form414528003_04152026.xml\"\n },\n {\n \"insider\": \"Jorey Chernett\",\n \"role\": \"Director / 10% Owner\",\n \"amount_usd\": 145500,\n \"date\": \"2026-03-23\",\n \"source_url\": \"https://www.sec.gov/Archives/edgar/data/1870940/000092189526000802/xslF345X06/form414528003air_03252026.xml\"\n }\n ],\n \"insider_open_market_total_usd_90d\": 299100,\n \"distinct_insider_buyers_90d\": 1,\n \"ceo_buy_present\": false,\n \"cfo_buy_present\": false,\n \"material_insider_selling_90d_usd\": 0,\n \"notable_13f_holders\": [\n \"pending — v2\"\n ],\n \"politician_recent_buys\": [\n \"pending — v2\"\n ]\n },\n \"catalyst\": {\n \"next_earnings_date\": \"2026-08-07\",\n \"recent_eps_surprise_pattern\": \"Mixed: beat Q3 2025 by 33% but missed Q4 2025; latest Q1 2026 beat 50%. Company guiding to stabilization with first positive same-center sales in 2+ years.\",\n \"guidance_raise_in_last_90d\": true,\n \"named_catalysts\": [\n {\n \"type\": \"earnings\",\n \"description\": \"Q1 2026 results May 8, 2026: first positive same-store sales growth in >24 months (+1% Q1), reaffirmed FY2026 outlook for approximately flat same-center revenue.\",\n \"date_or_window\": \"2026-05-08 (reported); next Aug 7, 2026\",\n \"source_urls\": [\n \"https://finance.yahoo.com/sectors/healthcare/articles/airsculpt-technologies-reports-first-quarter-103000074.html\"\n ],\n \"directional_bias\": \"bullish\"\n },\n {\n \"type\": \"guidance\",\n \"description\": \"FY2026 reaffirmed at ~flat same-store revenue with Q1 positive inflection; London facility closure (non-core, UK market exit).\",\n \"date_or_window\": \"Ongoing FY2026\",\n \"source_urls\": [\n \"https://finance.yahoo.com/news/airsculpt-technologies-announces-intent-delay-104500105.html\"\n ],\n \"directional_bias\": \"bullish\"\n },\n {\n \"type\": \"regulatory\",\n \"description\": \"Q4 2025 earnings report required a corrected filing for Adjusted EBITDA miscalculation related to London closure — no fraud but reflects internal control weakness.\",\n \"date_or_window\": \"April 2, 2026 (corrected April 6)\",\n \"source_urls\": [\n \"https://finance.yahoo.com/sectors/healthcare/articles/correction-airsculpt-technologies-reports-fourth-103000744.html\"\n ],\n \"directional_bias\": \"ambiguous\"\n }\n ]\n },\n \"mispricing\": {\n \"forward_pe\": -233,\n \"sector_median_forward_pe\": null,\n \"ev_to_ebitda\": 50.981,\n \"sector_median_ev_to_ebitda\": null,\n \"fcf_yield_pct\": 3.96,\n \"sotp_gap_pct\": null,\n \"narrative\": \"No meaningful P/E given persistent losses; EV/EBITDA of ~51x is very high but somewhat justified by thin margins and turnaround narrative. FCF yield ~4% is modest. At $328M market cap vs ~$152M revenue, the company is priced for a recovery that may be slow in materializing.\"\n },\n \"quality\": {\n \"roic_pct\": null,\n \"gross_margin_trend_pp_yoy\": \"Stable at 66% (consistent with prior years)\",\n \"net_debt_to_ebitda\": 13.5,\n \"balance_sheet_grade\": \"C\"\n },\n \"technical\": {\n \"above_50dma\": true,\n \"above_200dma\": null,\n \"rsi_14\": 76.6,\n \"macd_recent_bullish_cross\": true,\n \"12_1_momentum_vs_sector_pct\": null\n }\n },\n \"price_context\": {\n \"last_close\": 4.66,\n \"ytd_return_pct\": -21.02,\n \"from_52w_high_pct\": 61.2\n },\n \"filings_reviewed\": [\n {\n \"form\": \"10-K\",\n \"filed\": \"2026-03-31\",\n \"url\": \"https://www.sec.gov/Archives/edgar/data/1870940/000187094026000011/airs-20251231.htm\",\n \"key_takeaways\": [\n \"FY2025 revenue flat YoY at $151.8M; same-store sales declined throughout year but improved to single-digit decline by December and turned positive in February 2026.\",\n \"London facility closed in FY25, UK market exit — non-recurring impairment charge.\",\n \"Adjusted EBITDA margin ~11%, down from higher levels historically as marketing investment and overhead remained elevated even with revenue decline.\",\n \"Debt: $71M term loan (A2022 Credit Agreement), revolver undrawn; D/E 70% is high but management emphasized debt paydown trajectory.\"\n ]\n },\n {\n \"form\": \"8-K\",\n \"filed\": \"2026-05-14\",\n \"url\": \"https://www.sec.gov/Archives/edgar/data/1870940/000187094026000031/airs-20260512.htm\",\n \"key_takeaways\": [\n \"Annual meeting: directors Adam Feinstein, Thomas Aaron, Kenneth Higgins re-elected; auditor ratification passed (with notable dissent: 24.3M against vs 41.5M for).\",\n \"RSU grants to three independent directors on May 12: each received 100,286 RSUs vesting in ~1 year — compensation, not open-market buys.\"\n ]\n },\n {\n \"form\": \"8-K\",\n \"filed\": \"2026-03-16\",\n \"url\": \"https://www.sec.gov/Archives/edgar/data/1870940/000187094026000005/airs-20260316.htm\",\n \"key_takeaways\": [\n \"Annual report delayed via Form 12b-25 due to London facility closure accounting adjustment; preliminary Q4 revenue $33.4M (16% same-store decline).\"\n ]\n }\n ],\n \"options_context\": {\n \"expiries_examined\": [\n \"2026-05-15\",\n \"2026-06-18\",\n \"2026-07-17\"\n ],\n \"iv_summary\": \"ATM IV extremely low on near-term expiries — the options chain data shows anomalous values (IV ~0.01% for ATM calls, very thin volume). Options market is essentially non-functional at normal pricing levels; likely illiquid small-cap with unreliable mid/bid/ask.\",\n \"notable_skew_or_flow\": \"Flow is bullish-biased ($214K net call notional vs $4K put) but with negligible open interest and unreliable IV data. Chernett's simultaneous purchase of calls on his own stock (collar behavior) suggests he views $4-$5 as a resistance zone.\"\n },\n \"competitive_landscape\": \"AirSculpt competes in the elective body contouring/cosmetic surgery market against Sienna Labs competitors, SculptMyBody franchisees, and broader wellness players. Competitive moat is primarily brand and surgeon relationships; minimal IP barrier to entry. The primary secular headwind is GLP-1 drugs (Ozempic/Wegovy) reducing patient demand for fat removal procedures — a risk acknowledged in the 10-K's Risk Factors.\",\n \"key_risks\": [\n \"GLP-1 drug competition directly cannibalizing addressable market for body contouring\",\n \"Revenue has been flat/declining for multiple quarters; turnaround is early-stage and unproven\",\n \"High leverage (D/E ~70%) constrains financial flexibility\",\n \"London closure accounting required correction to Adjusted EBITDA — internal control flag\",\n \"Annual report delayed; audit/control environment is weaker than larger peers\",\n \"RSI 76.6: stock has already tripled from January lows before Chernett's buys fully matured\",\n \"Chernett selling covered calls ($4C, $5C) indicates he doesn't expect near-term breakout above $5\",\n \"Small-cap with thin options liquidity — spreads may be wide\"\n ],\n \"what_the_market_might_be_missing\": \"The first positive same-store sales print in 2+ years (Q1 2026 +1%) is a genuine operational inflection that the market has partially priced but may not have fully credited as durable. Chernett, who controls ~10% of the company and bought open-market at $2.54-$2.91 (now $4.66), provides a floor of informed-holder conviction. However, this signal is somewhat undermined by his simultaneous sale of call options against his position — suggesting he views $4-5 as resistance rather than an undervaluation threshold.\",\n \"anti_signals_present\": [\n \"dilution\",\n \"accounting\"\n ],\n \"sources\": [\n {\n \"label\": \"Q1 2026 earnings release\",\n \"url\": \"https://finance.yahoo.com/sectors/healthcare/articles/airsculpt-technologies-reports-first-quarter-103000074.html\"\n },\n {\n \"label\": \"FY2025 10-K filing\",\n \"url\": \"https://www.sec.gov/Archives/edgar/data/1870940/000187094026000011/airs-20251231.htm\"\n },\n {\n \"label\": \"Annual report delay / Q4 correction 8-K\",\n \"url\": \"https://www.sec.gov/Archives/edgar/data/1870940/000187094026000005/airs-20260316.htm\"\n },\n {\n \"label\": \"Form 4 — Chernett April 17 P purchase\",\n \"url\": \"https://www.sec.gov/Archives/edgar/data/1870940/000092189526001030/xslF345X06/form414528003_04202026.xml\"\n },\n {\n \"label\": \"Form 4 — Chernett March 23 collar transaction\",\n \"url\": \"https://www.sec.gov/Archives/edgar/data/1870940/000092189526000802/xslF345X06/form414528003air_03252026.xml\"\n }\n ],\n \"unfetched_signals\": [\n \"13f_deltas\",\n \"politician_trades\",\n \"sentiment_score\"\n ]\n}\n\nOutput ONLY the decision JSON described in the system prompt. Do NOT\ninclude ... reasoning blocks — they eat the output token\nbudget and produce truncated, unparseable decisions.", "completions": [ { "ts": "2026-05-14T10:58:54.767Z", "raw_content": "The dossier is for AIRS (AirSculpt Technologies, Inc.).\nScout verdict: range_bound_or_income\nAnti-signal present: \"dilution\", \"accounting\"\nLet's check the rubric and scoring.\n\nA. SMART-MONEY CLUSTER (max 25)\n- Insider purchases: Jorey Chernett (Director/10% owner) bought ~$300K.\n- Distinct buyers: 1. Amount: ~$300K. (< $500K, < $5M)\n- CEO/CFO buy: false.\n- 13F: pending.\n- Politician: pending.\n- Penalty: none (selling is covered calls, not material insider selling > buying in dollars? Actually, covered calls are hedging, not selling stock. The prompt says \"material insider SELLING > BUYING in dollars\". Chernett bought $300K, sold calls. Not stock selling. So no penalty.)\nScore: 0 pts. (Only 1 buyer, <$500k).\n\nB. OPTIONS FLOW / UOA (max 10)\n- IV is extremely low, options market non-functional.\n- Flow bullish but negligible OI.\nScore: 0 pts.\n\nC. CATALYST (max 25)\n- Next earnings: Aug 7, 2026. (Not within 90 days from May 2026? Wait, Q1 results reported May 8. Next is Aug 7. That's ~80 days away. But EPS surprise pattern mixed.)\n- Guidance raise: FY26 reaffirmed at ~flat. Not a raise.\n- Quantifiable sector tailwind: None, actually headwind from GLP-1.\nScore: 0 pts.\n\nD. MISPRICING (max 15)\n- Forward P/E: -233 (negative)\n- EV/EBITDA: ~51x (high)\n- FCF yield: 3.96%\n- SOTP: null\nScore: 0 pts.\n\nE. QUALITY (max 15)\n- ROIC: null\n- Gross margin: stable at 66% (not expanding >= 3pp)\n- Net debt/EBITDA: 13.5 (>> 2x)\nScore: 0 pts.\n\nF. MOMENTUM/TECHNICAL (max 10)\n- Above 50DMA: true (3 pts)\n- 12-1 momentum: null\n- RSI 14: 76.6 (overbought, not 40-65)\n- MACD bullish cross: true (1 pt)\nScore: 4 pts.\n\nTotal Score: ~4 pts.\nAnti-signal gates: \"dilution\", \"accounting\". The dossier mentions \"annual report delay due to accounting adjustments\" and \"corrected filing for Adjusted EBITDA miscalculation\". This triggers the accounting gate. Also dilution gate.\nRisk class: market cap ~$328M -> asymmetric.\nThresholds for asymmetric: < 60 Skip.\nScore is well below 60.\nReason: Weak fundamentals, high leverage, accounting irregularities (annual report delay/EBITDA correction), and options market illiquidity make this unsuitable for a publishable thesis. The stock has already tripled from lows, and the insider's collar strategy signals resistance, not conviction.\n\nI will output the skip JSON.\nCheck structure:\n{\n \"skip\": true,\n \"score\": 4,\n \"score_breakdown\": {\n \"smart_money\": 0,\n \"options_flow\": 0,\n \"catalyst\": 0,\n \"mispricing\": 0,\n \"quality\": 0,\n \"technical\": 4\n },\n \"reason\": \"Score is 4, well below the 60 threshold for asymmetric small-caps. The dossier flags material accounting irregularities (annual report delay and EBITDA correction) and dilution, which trigger hard anti-signal gates. Additionally, weak fundamentals (13.5x net debt/EBITDA, negative earnings), an overbought technical setup (RSI 76.6), and an insider who hedges with collars rather than showing unhedged conviction eliminate any viable trade shape.\"\n}\nWait, let's verify the scoring carefully.\nA: 0\nB: 0\nC: 0\nD: 0\nE: 0\nF: 4 (3 for above 50DMA, 1 for MACD cross)\nTotal: 4.\nAnti-signal gates: \"dilution\", \"accounting\". The prompt says \"If scoring_inputs has anti_signals_present non-empty, treat each entry as a gate; skip unless you can articulate WHY it doesn't apply to this case.\"\nI will articulate why it doesn't apply or just state it triggers the gate. Actually, the accounting adjustment is a red flag, and dilution is present. I'll just note it triggers the gate.\nThe output format is strict. I will produce the JSON.\nOne minor point: The prompt says \"ONLY ONE STRUCTURE TYPE. Pick long_stock, csp, OR cc and only fill that sub-object.\" but since I'm skipping, I just output the skip JSON.\nI will ensure the JSON matches the skip schema exactly.\nCheck fields: \"skip\", \"score\", \"score_breakdown\", \"reason\".\nAll good.\nProceed. \nLet's double check F scoring: \"3 pts: above both 50DMA and 200DMA\" -> only above 50DMA, so 0 for that line. \"1 pt: MACD bullish cross in last 30 days\" -> 1 pt. So technical is 1.\nWait, the rubric says:\n• 3 pts: above both 50DMA and 200DMA\n• 4 pts: 12-1 month price return positive AND beating sector\n• 2 pts: RSI 14 in 40-65 zone\n• 1 pt: MACD bullish cross in last 30 days\nSo technical = 1.\nTotal = 1.\nI'll score it 1.\nReason covers it.\nReady. \nOutput matches exactly. \nProceeds. \n{\n \"skip\": true,\n \"score\": 1,\n \"score_breakdown\": {\n \"smart_money\": 0,\n \"options_flow\": 0,\n \"catalyst\": 0,\n \"mispricing\": 0,\n \"quality\": 0,\n \"technical\": 1\n },\n \"reason\": \"Score is 1, far below the 60 threshold for asymmetric small-caps. The dossier flags material accounting irregularities (annual report delay and EBITDA correction) and dilution, which trigger hard anti-signal gates. Additionally, weak fundamentals (13.5x net debt/EBITDA, negative earnings), an overbought technical setup (RSI 76.6), and an insider who hedges with collars rather than showing unhedged conviction eliminate any viable trade shape.\"\n}\nWait, let's verify the \"above both 50DMA and 200DMA\" rule. It says 3 pts if above both. It's only above 50DMA. So 0.\nTechnical score = 1.\nEverything else is 0.\nTotal = 1.\nMatches.\nOutput matches schema.\nDone. \nOne thing: The prompt says \"If scoring_inputs has anti_signals_present non-empty, treat each entry as a gate; skip unless you can articulate WHY it doesn't apply to this case.\" I will mention that in the reason.\nAll good. \nProceeds. \nOutput generation. \n(Self-Correction/Refinement during thought)\nLet's re-read the anti-signal gate rule: \"If scoring_inputs has anti_signals_present non-empty, treat each entry as a gate; skip unless you can articulate WHY it doesn't apply to this case.\"\nThe dossier has: \"dilution\", \"accounting\".\nI will state that these gates are triggered and cannot be safely overridden given the context (accounting delay/EBITDA correction indicates control weakness; dilution overhang exists).\nThe score is definitely <60.\nI will output the JSON exactly as requested.\nDone. \nOutput matches. \nProceeds. \n[Final Check of the Prompt]\n\"ONLY ONE STRUCTURE TYPE. Pick long_stock, csp, OR cc and only fill that sub-object. Leave the others null/omitted.\" -> This applies to IF YOU PROCEED.\nSince I am skipping, I output the skip JSON.\nAll good. \nOutput Generation. \n```json\n{\n \"skip\": true,\n \"score\": 1,\n \"score_breakdown\": {\n \"smart_money\": 0,\n \"options_flow\": 0,\n \"catalyst\": 0,\n \"mispricing\": 0,\n \"quality\": 0,\n \"technical\": 1\n },\n \"reason\": \"Score is 1, far below the 60 threshold for asymmetric small-caps. The dossier flags material accounting irregularities (annual report delay and EBITDA correction) and dilution, which trigger hard anti-signal gates. Additionally, weak fundamentals (13.5x net debt/EBITDA, negative earnings), an overbought technical setup (RSI 76.6), and an insider who hedges with collars rather than showing unhedged conviction eliminate any viable trade shape.\"\n}\n```\nMatches requirements. No extra text. Valid JSON. Done. \nProceeds. \n(Self-Correction/Note during generation prep)\nWait, the prompt says \"ONLY ONE STRUCTURE TYPE. Pick long_stock, csp, OR cc and only fill that sub-object.\" This is under \"IF YOU PROCEED\". Since I'm skipping, I just output the skip object.\nI will ensure strict JSON formatting.\nDone. \nOutput matches. \nProceeds. \n[Output Generation] -> *Proceeds*\n\n\n{\n \"skip\": true,\n \"score\": 1,\n \"score_breakdown\": {\n \"smart_money\": 0,\n \"options_flow\": 0,\n \"catalyst\": 0,\n \"mispricing\": 0,\n \"quality\": 0,\n \"technical\": 1\n },\n \"reason\": \"Score is 1, far below the 60 threshold for asymmetric small-caps. The dossier flags material accounting irregularities (annual report delay and EBITDA correction) and dilution, which trigger hard anti-signal gates. Additionally, weak fundamentals (13.5x net debt/EBITDA, negative earnings), an overbought technical setup (RSI 76.6), and an insider who hedges with collars rather than showing unhedged conviction eliminate any viable trade shape.\"\n}", "cleaned_content": "{\n \"skip\": true,\n \"score\": 1,\n \"score_breakdown\": {\n \"smart_money\": 0,\n \"options_flow\": 0,\n \"catalyst\": 0,\n \"mispricing\": 0,\n \"quality\": 0,\n \"technical\": 1\n },\n \"reason\": \"Score is 1, far below the 60 threshold for asymmetric small-caps. The dossier flags material accounting irregularities (annual report delay and EBITDA correction) and dilution, which trigger hard anti-signal gates. Additionally, weak fundamentals (13.5x net debt/EBITDA, negative earnings), an overbought technical setup (RSI 76.6), and an insider who hedges with collars rather than showing unhedged conviction eliminate any viable trade shape.\"\n}", "tool_calls": null, "finish_reason": "stop" } ], "tool_results": [], "final_message": "{\n \"skip\": true,\n \"score\": 1,\n \"score_breakdown\": {\n \"smart_money\": 0,\n \"options_flow\": 0,\n \"catalyst\": 0,\n \"mispricing\": 0,\n \"quality\": 0,\n \"technical\": 1\n },\n \"reason\": \"Score is 1, far below the 60 threshold for asymmetric small-caps. The dossier flags material accounting irregularities (annual report delay and EBITDA correction) and dilution, which trigger hard anti-signal gates. Additionally, weak fundamentals (13.5x net debt/EBITDA, negative earnings), an overbought technical setup (RSI 76.6), and an insider who hedges with collars rather than showing unhedged conviction eliminate any viable trade shape.\"\n}", "tool_calls_total": 0, "walltime_ms": 62611, "stop_reason": "stop", "completed_at": "2026-05-14T10:58:54.768Z" }